40 Hz light preserves synaptic plasticity and mitochondrial function in Alzheimer's disease model

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Alzheimer's disease (AD) is the leading cause of dementia, characterized by mitochondrial dysfunction, oxidative stress, and ion channel compromise.
• The precise mechanisms underlying the therapeutic effects of flickering light therapy for AD remain largely unexplored.
• Existing research suggests potential benefits of flickering light stimulation in addressing AD pathology.

Purpose of the Study:

• To investigate the efficacy of 40 Hz flickering light therapy in an established rat model of Alzheimer's disease.
• To elucidate the underlying mechanisms by which flickering light therapy impacts cognitive function, synaptic plasticity, and mitochondrial health in AD.
• To evaluate the effects of 40 Hz light therapy on key biomarkers associated with AD progression.

Main Methods:

• Alzheimer's disease was induced in rats via intracerebroventricular streptozotocin (STZ) injections.
• Following STZ administration, rats were subjected to daily 15-minute sessions of 40 Hz flickering light for seven consecutive days.
• Cognitive performance was assessed using behavioral tests, and biochemical analyses measured oxidative stress, neurotransmitter levels, and mitochondrial function.

Main Results:

• STZ-induced AD rats displayed significant cognitive deficits, increased oxidative stress, amyloid-beta deposition, altered neurotransmitter levels, and mitochondrial dysfunction.
• Flickering light therapy effectively ameliorated cognitive decline and preserved synaptic plasticity in AD rats.
• The treatment normalized mitochondrial metabolites and restored the activity of the ATP-insensitive mitochondrial calcium-sensitive potassium (mitoBKCa) channel.

Conclusions:

• 40 Hz flickering light therapy demonstrates significant therapeutic potential for Alzheimer's disease.
• The therapy preserves cognitive function and synaptic plasticity by restoring mitochondrial function and normalizing mitoBKCa channel activity.
• Flickering light therapy represents a promising non-invasive approach for treating neurodegenerative disorders like AD.